Mikael Alsterholm, Sahlgrenska Academy at the University of Gothenburg. Photo by: Karin Olsson Painful skin and trouble sleeping are...

Patients with atopic dermatitis (AD) are more likely to have eating disorders than patients without AD, and dermatologists may be in a...

Upadacitinib is efficacious and demonstrated a favorable benefit-risk profile for long-term treatment of AD in adolescents.

A combination of dupilumab and abrocitinib is effective in treating refractory AD in pediatric patients

A new study being presented at the 2024 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Boston...

In a study published in Clinical and Experimental Dermatology , researchers from Yale School of Medicine identified a significant...

Risk of pediatric AD is associated with childhood obesity and correlated to weight loss and gain.

Cendakimab is safe and efficacious in treating moderate-to-severe AD in adult patients.